back insurance patient resources Covid-19 Response request records first visit info Common Clinical Fees billing inquiries pay bill

Practice Locations

UCH - Anschutz Inpatient Pavilion
12605 E. 16th Ave Aurora, CO 80045

720-848-0000

Tomer Mark, MD

Physician

Board Certified

Schedule Appointment

Tomer Mark, MD

Physician

Board Certified

GENDER

Male

DEPARTMENT

Medicine

Specialty

Internal Medicine, Hematology, Medical Oncology

Primary Clinic Phone

(720) 848-6400

Locations

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court 3rd floor, Anschutz Cancer Pavilion, Aurora, CO 80045

720-848-6400

UCH - Anschutz Inpatient Pavilion
12605 E. 16th Ave Aurora, CO 80045

720-848-0000

Clinical Interest for Patients

Multiple myeloma and other plasma cell disorders


Care Philosophy

Not all myeloma cancers are the same; therefore tailoring the treatment to the patient is key to successful outcomes.


Specialties

  • Internal Medicine ( 2005 , 2015 )
  • Hematology ( 2008 , 2018 )
  • Medical Oncology ( 2008 , 2018 )

Conditions & Treatments

  • Cancers

    Amyloid, Blood and Marrow Transplant, Myeloma

Personal Interests

Dr. Mark earned a Bachelor of Science degree from Yale University, where he majored in Molecular Biochemistry and Biophysics. He received his Doctorate in Medicine with distinction in research from the State University of New York at Stony Brook. He then completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. Dr. Mark completed fellowship in Hematology and Medical Oncology in 2008 at Weill Cornell Medical College in New York City. He also received a Master of Science degree in Clinical Investigation from the Weill Cornell School of Graduate Sciences and completed the American Society of Hematology Clinical Research Training Institute during his fellowship training. After fellowship, Dr. Mark stayed on at Cornell and became associate director of the Multiple Myeloma Center and later director of the inpatient myeloma service at the New York Presbyterian Hospital, Cornell campus. In 2016, he joined the University of Colorado as clinical director of the plasma cell disorders program, which will cover conditions such as multiple myeloma, AL amyloidosis, light chain deposition disease, POEMS syndrome and other rare malignancies related to abnormal plasma cell function. Dr. Mark?s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. He is currently a member of the International Myeloma Working Group and co-chair of the plasma cell disease committee at the Center for International Blood and Marrow Transplant Research. He has been principal investigator on multiple early to late phase clinical trials as well as the author of several book chapters on the subject of plasma cell disorders. While clinical research is a major focus for Dr. Mark, his work also centers on providing the best patient experience possible. He has worked with patient advocacy groups as well alongside his patients to help improve care. He has also coauthored a book with one of his patients: ?Love, Olivia: A Stem Cell Transplant Story.?


Medical Schools

MD, The School of Medicine at Stony Brook University Medical Center (2002)


Undergraduate Schools

BS, Yale University (CT) (1998)


Internships

Beth Israel Deaconess Medical Center/Harvard Medical School Program


Residency Program

Beth Israel Deaconess Medical Center/Harvard Medical School Program (2005)


Fellowships

New York Presbyterian Hospital (Cornell Campus) Program (2008)

ASH, member


International Myeloma Society, member


International Myeloma Working Group, member


Research Interests for Patients

Dr. Mark?s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. As a clinical trialist, he has been principal investigator on phase 1 trials of new compounds for use in refractory myeloma and stem cell transplantation. He has also led phase 2 and 3 studies designed to maximize treatment efficacy in newly diagnosed and relapsed myeloma. As every myeloma is genetically distinct, his aim to develop and deliver personalized therapy for every patient based on scientific rationale.

information for referring providers

Clinical Interests for Referring Providers

Multiple myeloma and other plasma cell disorders


Referral Contact Phone: 720-848-6400